Medicine Oncology Prostate cancer Prognosis
Home > Disciplines > Medicine > Oncology > Prostate cancer > Prognosis
CONTENTS
OVERVIEW ■ OVERVIEW ON PREDICTION TOOLS AND OUTCOMES ■ INTEGRATIVE MEDICINE OUTCOMES ■ NATURAL HISTORY ■ NOMOGRAMS ■ PARTIN TABLES ■ RISK CLASSIFICATION ■ ONLINE PREDICTION TOOLS
TOOLS FOR PREDICTION OF LIFE EXPECTANCY (BEFORE TREATMENT) ■ PREDICTIONS ON LIFE EXPECTANCY
TOOLS FOR PREDICTION OF PATHOLOGICAL STAGE (BEFORE TREATMENT) ■ PREDICTION ON BIOPSY OUTCOME ■ PREDICTIONS AT INITIAL DIAGNOSIS ■ PREDICTION OF GRADE/STAGE BEFORE RADICAL PROSTATECTOMY ■ PREDICTION OF GLEASON SCORE UPGRADING ■ PREDICTION OF POSITIVE LIMPH NODES AND/OR EXTRAPROSTATIC EXTENSION
TOOLS FOR PREDICTION OF SURVIVAL AND CANCER-SPECIFIC MORTALITY (BEFORE/AFTER TREATMENT) ■ ALL-CAUSE MORTALITY ■ CONDITIONAL PROBABILITIES OF DEATH ■ DISEASE SPECIFIC MORTALITY After treatment ■ PREDICTIONS AT BCR AFTER RADICAL PROSTATECTOMY ■ PREDICTION OF SURVIVAL FOLLOWING BCR AFTER RP ■ PREDICTION OF SURVIVAL AFTER SALVAGE TREATMENT
TOOLS FOR PREDICTION OF BIOCHEMICAL RECURRENCE (BEFORE/AFTER TREATMENT) ■ PREDICTIONS ON MONITORING OUTCOMES ■ PREDICTION OF BCR USING GLEASON GRADE GROUPS ■ PREDICTIONS ON OUTCOMES OF USE OF COMMON MEDICATIONS ■ PREDICTIONS ON OUTCOMES OF USE OF STATINS Before treatment ■ PREDICTION OF BCR AFTER RP USING PRE-TREATMENT DATA After treatment ■ PREDICTIONS ON OUTCOMES AFTER PRIMARY TREATMENT ■ PREDICTIONS ON (PRIMARY) RADICAL PROSTATECTOMY OUTCOMES ■ PREDICTIONS ON OUTCOMES OF PRIMARY RADIOTHERAPY ■ PREDICTION OF BCR AFTER RP USING POST-TREATMENT DATA ■ PREDICTION OF TIME TO BCR AFTER RADICAL PROSTATECTOMY ■ PREDICTIONS ON OUTCOMES OF NEOADJUVANT ADT ■ PREDICTIONS ON OUTCOMES AFTER SALVAGE TREATMENT ■ PREDICTIONS ON OUTCOMES OF RADIOTHERAPY FOLLOWING PRIMARY RP ■ PREDICTIONS ON OUTCOMES OF PELVIC IRRADIATION ■ PREDICTIONS ON OUTCOMES OF RP FOLLOWING PRIMARY RADIOTHERAPY Clinical recurrence ■ PREDICTION OF CLINICAL RECURRENCE AFTER RADICAL PROSTATECTOMY
TOOLS FOR PREDICTION OF METASTATIC PROGRESSION (AFTER TREATMENT) ■ PREDICTION OF METASTASIS AFTER PRIMARY TREATMENT ■ PREDICTION OF CASTRATION RESISTANCE
TOOLS FOR PREDICTION OF SECOND CANCER (AFTER TREATMENT) ■ PREDICTION OF SECOND CANCER AFTER PRIMARY/SALVAGE TREATMENT
BIOMARKERS AND GENOMICS ■ AGE AT DIAGNOSIS ■ CIRCULATING TUMOR CELLS ■ GLEASON SCORE ■ IMAGING ■ METABOLIC FACTORS ■ NEUTROPHIL TO LYMPHOCITE RATIO ■ POSITIVE BIOPSY CORES ■ POSITIVE SURGICAL MARGINS ■ PCA3 AND OTHER PROSTATE ANTIGENS ■ PROSTATE CANCER RISK INDEX (PRIX) ■ PSA AFTER RP ■ PSA AFTER RT FOLLOWING RP ■ PSA AT DIAGNOSIS ■ PSA DENSITY ■ PSA KINETICS ■ SURGEON EXPERIENCE ■ TESTOSTERONE AND OTHER HORMONES ■ TIME UNTIL TREATMENT ■ TUMOR CONTACT LENGHT ■ TUMOR VOLUME
PREDICTION OF OUTCOMES BY CLASS OF PATIENTS ■ OLDER PATIENTS ■ PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER ■ PATIENTS WITH DIABETES ■ PATIENTS WITH FAMILY HISTORY ■ PATIENTS WITH HIGH-RISK PROSTATE CANCER ■ PATIENTS WITH LOCALIZED PROSTATE CANCER ■ PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER ■ PATIENTS WITH NEWLY DIAGNOSED METASTATIC PROSTATE CANCER ■ PATIENTS WITH OLIGOMETASTATIC PROSTATE CANCER ■ PATIENTS WITH ELEVATED PSA AS SOLE PREOPERATIVE RISK FEATURE ■ YOUNGER PATIENTS
